As­traZeneca and Io­n­is claim a PC­SK9 win, but will it mat­ter in a crowd­ed mar­ket?

The first gen­er­a­tion of PC­SK9 block­ers was, rough­ly speak­ing, a com­mer­cial dis­as­ter for their de­vel­op­ers, Sanofi and Am­gen.

Al­though they suc­cess­ful­ly low­ered bad cho­les­terol and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER